Sirtex Medical to sponsor FAST clinical trial:
Update on Clinical Trial Evaluating SIR-Spheres Microspheres with Bevacizumab and Chemotherapy as a First-Line Treatment for Unresectable Metastatic Colorectal Cancer

Sydney Australia, 13 April 2007: Biotechnology and medical device company Sirtex Medical Limited (SRX) is pleased to announce that it has decided to become the industry sponsor of the FAST clinical trial, the first clinical trial to evaluate the safety of concurrent administration of Selective Internal Radiation Therapy using SIR-Spheres® microspheres; bevacizumab, an anti-angiogenic agent; and FOLFOX6 or FOLFIRI or IFL chemotherapy regimens as first-line treatment of patients with colorectal cancer that has metastasized to the liver.

As announced to the Australian Stock Exchange on 8 February, 2007, Sirtex was supporting the US-based investigator-run FAST clinical trial, led by principal investigator, Andrew S. Kennedy, M.D., co-Medical Director of Wake Radiology Oncology in Cary, North Carolina USA. However following discussion and agreement with Dr Kennedy Sirtex has opted to become industry sponsor and will apply for an Investigational Device Exemption (IDE) from the US FDA, a necessary prerequisite for such a clinical trial when being conducted by an industry sponsor.

The clinical trial will be temporarily halted while Sirtex files its IDE application with the FDA. When the clinical trial recommences, it will be led by Dr Dennis Carter, Radiation Oncologist from Rocky Mountain Cancer Center, Denver, Colorado, USA.

About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres

Selective Internal Radiation Therapy (SIRT) is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumours. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumours with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumour activity, and improved quality of life. SIRT has been found to shrink liver tumours more than chemotherapy alone.

SIRT using SIR-Spheres microspheres is approved for use in Australia, New Zealand, the United States of America (FDA approval), European Union (CE Mark), Hong Kong, Malaysia, Singapore, Thailand, Israel, and India. SIRT is available in 140 treatment centres around the world, and more than 6500 patients have been treated to date.

® SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd
About Liver Cancer

Liver cancer is the biggest cancer-related killer of adults in the world. Each year, more than 500,000 new cases of primary liver cancer develop worldwide and at least 200,000 new cases of secondary liver cancer develop from primary bowel cancer alone. It is estimated that secondary liver cancer is the ultimate cause of death for one in three cancer sufferers. Liver tumours are inoperable in 90 per cent of cases, and are typically incurable with chemotherapy.

For more information, visit our website at www.sirtex.com

Contact: Gilman Wong, CEO, +61-2-9936-1400